Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMcibr2108679 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mesothelial cell responses to acute appendicitis or small bowel obstruction reactive ascites: Insights into immunoregulation of abdominal adhesion.
PLoS One
January 2025
Trauma Research, Swedish Medical Center, Englewood, Colorado, United States of America.
Previous abdominal surgery (PAS) increases risk of small bowel obstruction (SBO) due to adhesions, and appendectomy (appy) is an independent risk factor for abdominal adhesion-related complications. Peritoneal inflammation, e.g.
View Article and Find Full Text PDFManagement of mucogingival defect following excision of multiple gingival squamous cell papillomas using VISTA - A case report with 24 months follow-up.
J Indian Soc Periodontol
December 2024
VISTA Institute for Therapeutic Innovations, California, USA.
Oral squamous cell papilloma is a benign proliferation of the stratified squamous epithelium, associated with the human papillomavirus (HPV). The clinical manifestation includes papillary or verrucous exophytic mass. Complete excision of the lesion, including normal margins, followed by histopathological examination is the treatment of choice.
View Article and Find Full Text PDFMapping the Binding Hotspots and Transient Binding Pockets on V-Domain Immunoglobulin Suppressor of T Cell Activation Protein Surface.
ACS Omega
December 2024
School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, China.
V-domain immunoglobulin suppressor of T cell activation (VISTA), an inhibitory immune checkpoint present on both immune and tumor cells, has emerged as a highly promising target for cancer therapy due to its potential to overcome resistance encountered with existing immune checkpoint treatments. VSIG-3 is determined as an inhibitory ligand for VISTA, leading to the suppression of T cell proliferation. However, hotspots between VISTA/VSIG-3 protein-protein interaction remain ambiguous, mainly attributed to the lack of the structure of the VISTA/VSIG-3 complex.
View Article and Find Full Text PDFArginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells.
Immunol Res
December 2024
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Arginine vasopressin (AVP) has disparate impacts on immune responses by divergent receptors on cells including DCs. This study was conducted with the aim of investigating the impact of AVP on the maturation and expression of the inhibitory immune checkpoint molecules in tolerogenic monocyte-derived DCs. CD14 marker was used to separate monocytes from peripheral blood mononuclear cells (PBMCs) by MACS method.
View Article and Find Full Text PDFIdentification of VISTA regulators in macrophages mediating cancer cell survival.
Sci Adv
November 2024
Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Numerous human cancers have exhibited the ability to elude immune checkpoint blockade (ICB) therapies. This type of resistance can be mediated by immune-suppressive macrophages that limit antitumor immunity in the tumor microenvironment (TME). Here, we elucidate a strategy to shift macrophages into a proinflammatory state that down-regulates V domain immunoglobulin suppressor of T cell activation (VISTA) via inhibiting AhR and IRAK1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!